PSTI
Pluristem Therapeutics, Inc.
NasdaqCM
People also watch:CUROPXAOSIRATHXNBS
1.530.02 (1.32%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close1.51
Open1.51
Bid1.52 x 1100
Ask1.53 x 500
52wk Range0.71 - 2.45
Day's Range1.51 - 1.53
Volume75,299
Avg Vol (3m)129,396
As of 4:00 PM EDT. Market closed.
  • Japan is Breathing Life into the Stem Cell Space, Astellas Pharma (ALPMF) & Pluristem Therapeutics Inc. (PSTI) Are Benefiting
    Insider Monkey3 days ago

    Japan is Breathing Life into the Stem Cell Space, Astellas Pharma (ALPMF) & Pluristem Therapeutics Inc. (PSTI) Are Benefiting

    Japan is the stem cell capital of the world. From the Nobel winning efforts of Shinya Yamanaka in the field of mature to pluripotent stem cell reprogramming, to the STAP scandal and its suicide tarnished fallout, if there’s something to talk about in the sector, chances are it happened first in Japan. Japan’s development of […]

  • Pluristem Therapeutics, Inc. – Value Analysis (NASDAQ:PSTI) : July 19, 2016
    Capital Cube5 days ago

    Pluristem Therapeutics, Inc. – Value Analysis (NASDAQ:PSTI) : July 19, 2016

    Click here to see latest analysisCapitalcube gives Pluristem Therapeutics, Inc. a score of 28.Our analysis is based on comparing Pluristem Therapeutics, Inc. with the following peers – Vericel Corporation, Osiris Therapeutics, Inc., Athersys, Inc., Immunomedics, Inc., Cleveland BioLabs, Inc., Celgene Corporation, United Therapeutics Corporation, Caladrius Biosciences, Inc., Shenzhen Expressway Co., Ltd. Unsponsored ADR Class H […] (Read more...) The post Pluristem Therapeutics, Inc. – Value Analysis (NASDAQ:PSTI) : July 19, 2016 appeared first on CapitalCube.